Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc purchased 468,356 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $12.48 per share, with a total value of $5,845,082.88. Following the completion of the purchase, the director now directly owns 16,802,141 shares of the company’s stock, valued at approximately $209,690,719.68. This represents a 2.87 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The stock was purchased at an average price of $11.49 per share, with a total value of $3,684,728.10.
- On Friday, January 17th, Ecor1 Capital, Llc purchased 19,748 shares of Zymeworks stock. The shares were purchased at an average cost of $13.87 per share, for a total transaction of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc acquired 39,029 shares of Zymeworks stock. The stock was acquired at an average cost of $14.01 per share, with a total value of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The shares were acquired at an average cost of $13.39 per share, for a total transaction of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were acquired at an average cost of $13.13 per share, with a total value of $2,679,806.74.
- On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The stock was bought at an average price of $14.07 per share, with a total value of $295,765.47.
- On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The shares were bought at an average price of $14.78 per share, for a total transaction of $2,333,466.40.
- On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The shares were bought at an average price of $14.47 per share, with a total value of $853,556.36.
- On Tuesday, December 24th, Ecor1 Capital, Llc bought 11,958 shares of Zymeworks stock. The stock was bought at an average cost of $14.12 per share, for a total transaction of $168,846.96.
- On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The shares were purchased at an average price of $14.38 per share, with a total value of $240,030.96.
Zymeworks Stock Performance
Shares of ZYME stock opened at $12.25 on Friday. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70. The business’s fifty day moving average is $13.86 and its 200-day moving average is $13.66. The stock has a market cap of $852.32 million, a PE ratio of -8.17 and a beta of 1.13.
Institutional Investors Weigh In On Zymeworks
Wall Street Analyst Weigh In
Several brokerages recently weighed in on ZYME. HC Wainwright lifted their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, March 10th. Lifesci Capital initiated coverage on Zymeworks in a report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price target on the stock. Wells Fargo & Company raised their target price on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. Citigroup increased their price target on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. upgraded shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a research note on Monday, December 16th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Zymeworks currently has an average rating of “Moderate Buy” and an average target price of $21.00.
Check Out Our Latest Stock Analysis on ZYME
Zymeworks Company Profile
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Read More
- Five stocks we like better than Zymeworks
- What is a Bond Market Holiday? How to Invest and Trade
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Invest in Small Cap Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- 3 Healthcare Dividend Stocks to Buy
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.